Document is current

Article History

Received: 10 December 2024

Accepted: 14 July 2025

First Online: 13 August 2025

Change Date: 28 August 2025

Change Type: Update

Change Details: The author Bernard Le Foll name in citation details has been corrected from Foll BL to Le Foll B.

Declarations

:

: Dr. Bozinoff has received salary support from US National Institute on Drug Abuse (NIDA) grant R25-DA037756, unrelated to this work. She reports research grant funding from the Academic Health Sciences Innovation Fund, Womenmind, Canadian Institutes of Health Research (CIHR), Department of Family and Community Medicine–University of Toronto, and the Canadian College of Family Physicians. She has received honoraria for continuing professional development work from the Ontario College of Family Physicians and CAMH Education, unrelated to this work. Dr. Sloan has received research support from the CIHR, Health Canada, the Ontario Ministry of Health and Long-Term Care, the CAMH Foundation, and the Academic Health Sciences Centre AFP Innovation Fund. Dr. Sloan is also supported in part by an Academic Scholar Award from the Department of Psychiatry, University of Toronto. Dr. Sloan has received travel support from the Society of Biological Psychiatry and the International Society for CNS Clinical Trials and Methodology. He has received an honorarium for giving a talk at the McGill University Health Centre. Dr. Le Foll has obtained funding from Indivior for a clinical trial sponsored by Indivior. Dr. Le Foll has in-kind donations of placebo edibles from Indiva. Dr. Le Foll has obtained industry funding from Canopy Growth Corporation (through research grants handled by the Centre for Addiction and Mental Health and the University of Toronto). He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and is part of Steering Board for a clinical trial for Indivior. He is part of the Scientific Advisory Board of NFL Biosciences. He has been consultant for Shinogi, Changemark and ThirdBridge. He got travel support to attend an event by Bioprojet. He is supported by CAMH, Waypoint Centre for Mental Health Care, a clinician-scientist award from the department of Family and Community Medicine of the University of Toronto and a Chair in Addiction Psychiatry from the Department of Psychiatry of University of Toronto. Dr. Tang has received research support through the Brain & Behavior Research Foundation, CIHR (SCT– 191291), the Physician Services Incorporated Foundation, the National Institute on Drug Abuse (R21DA061350), and the Labatt Family Network for Research on the Biology of Depression. Dr. Quilty has received research support from Wellcome Trust, CIHR, Health Canada, Ontario Brain Institute, Gambling Research Exchange Ontario and CAMH Foundation. The other authors declare no conflicts of interest.